retatrutide clinical trials countries Underrepresentation Overconsumption Exploring The Gap In Global Trial Diversity October 27, 2025: U.K. regulators
Description
However, true sinus headaches are quite rare
10.2337/dc12-2504 [DOI] [PMC free article] [PubMed] [Google Scholar] 46.Meier JJ, Nauck MA
The decision to continue, taper, or stop should be individualized, not driven by arbitrary timelines
These insights can support a more personalized conversation with your healthcare provider about medication selection and dosing strategy
Polonsky KS, Rubenstein AH
It is important to note that GLP-1 receptor agonists are not FDA-approved specifically for the treatment of MASLD or MASH, though they may be used off-label in appropriate patients
